NeuroDiscovery to expand into UK

Perth-headquartered neurology-research company NeuroDiscovery has announced an agreement through its 100 per cent-owned subsidiary NeuroSolutions that will see it expand into the United Kingdom.

NeuroSolutions has signed an agreement with private drug company Xention Discovery to pursue multiple joint development opportunities.

The company has also entered into an agreement to acquire an electrophysiology device from Denmark company, Sophion Bioscience to cater for the increased demand for NeuroSolution's electrophysiology services.

The device will be operational in three months and will allow NeuroSolutions to increase revenues without the need to recruit additional staff.

The company will establish a presence in Cambridge in the UK from which it hopes to expand its business development activities in what is Europe's biggest life science community.